Your browser doesn't support javascript.
loading
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.
Wu, Yan-Lin; Lin, Zheng-Jun; Li, Chang-Chun; Lin, Xiao; Shan, Su-Kang; Guo, Bei; Zheng, Ming-Hui; Li, Fuxingzi; Yuan, Ling-Qing; Li, Zhi-Hong.
Afiliación
  • Wu YL; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Lin ZJ; Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Li CC; Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Lin X; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Shan SK; Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Guo B; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Zheng MH; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Li F; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Yuan LQ; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Li ZH; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. allenylq@csu.edu.cn.
Signal Transduct Target Ther ; 8(1): 98, 2023 03 02.
Article en En | MEDLINE | ID: mdl-36864020
ABSTRACT
Epigenetics regulates gene expression and has been confirmed to play a critical role in a variety of metabolic diseases, such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), osteoporosis, gout, hyperthyroidism, hypothyroidism and others. The term 'epigenetics' was firstly proposed in 1942 and with the development of technologies, the exploration of epigenetics has made great progresses. There are four main epigenetic mechanisms, including DNA methylation, histone modification, chromatin remodelling, and noncoding RNA (ncRNA), which exert different effects on metabolic diseases. Genetic and non-genetic factors, including ageing, diet, and exercise, interact with epigenetics and jointly affect the formation of a phenotype. Understanding epigenetics could be applied to diagnosing and treating metabolic diseases in the clinic, including epigenetic biomarkers, epigenetic drugs, and epigenetic editing. In this review, we introduce the brief history of epigenetics as well as the milestone events since the proposal of the term 'epigenetics'. Moreover, we summarise the research methods of epigenetics and introduce four main general mechanisms of epigenetic modulation. Furthermore, we summarise epigenetic mechanisms in metabolic diseases and introduce the interaction between epigenetics and genetic or non-genetic factors. Finally, we introduce the clinical trials and applications of epigenetics in metabolic diseases.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Epigénesis Genética / Enfermedades Metabólicas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Signal Transduct Target Ther Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Epigénesis Genética / Enfermedades Metabólicas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Signal Transduct Target Ther Año: 2023 Tipo del documento: Article País de afiliación: China